


February 2021 | Issue 4



# Community for a Cure Newsletter from the USC Norris Comprehensive Cancer Center

## From the Director: The USC Norris Comprehensive Cancer Center (USC Norris) is an



innovative leader in the cancer field, setting a global standard for cutting edge research to prevent, detect, and treat cancer. We are proud to be a magnet for the best minds in cancer research, cancer education, and delivery of patient-centered care. We continue to foster team science at USC Norris through the new Team

Science Accelerator Program. The goal of this new \$8M initiative is to encourage new teams of scientists and clinicians to come together to change the paradigm of cancer discovery, innovation, and cancer care. So far, we have funded two exemplary teams, one focused on new treatments for colorectal cancer and one focused on a new

immune therapy approach to treating multiple cancers. We hope you enjoy this February newsletter which includes the scientific discoveries of USC Norris members, a new faculty member spotlight, resources for patients and their loved ones, and an inspiring story from a USC Norris cancer survivor and patient.


Cayn Leman

**Director, USC Norris Comprehensive Cancer Center Associate Dean for Cancer Programs** H. Leslie and Elaine S. Hoffman Cancer Research Chair

Caryn Lerman, PhD

News

### CLINICAL **CANCER** RESEARCH



"Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer" Prostate cancer is the most common malignancy and the second most common cause of cancer death in U.S. men. Hormone therapy can extend the survival of many patients with prostate cancer, but for some, the disease continues to progress. In a phase III randomized trial for men with newly diagnosed metastatic prostate cancer, Dr. Goldkorn and his colleagues identified circulating tumor cells from a single tube of blood and found that they could predict which patients

for Translational Research, publishes results from a

national phase III trial in Clinical Cancer Research:

will respond to hormonal therapy and continue to respond two years later, and which patients will experience disease progression. This is the very first discovery of a bloodbased biomarker that predicts the success of hormonal therapy for prostate cancer and lays the foundation for its use in the clinic.

project to develop a micro-engineered colorectal

The 5-year survival rate for metastatic colorectal cancer (CRC) remains

**LINK TO PUBLICATION>> USC Norris member Shannon Mumenthaler receives** National Cancer Institute (NCI) R01 funding for her

cancer-on-a-chip model


### at 11% despite the availability of new therapies. USC Norris member Dr. Shannon Mumenthaler received an NCI R01 to develop a micro-engineered colorectal cancer-on-a-chip model, which is a 3D model that reflects the biological activities and responses of tumor cells. Mumenthaler and colleagues will use this novel laboratory model to identify factors that influence the behavior of tumor cells and how they respond to different treatments, providing new data to inform drug development for this disease. This

project is in collaboration with Drs. Heinz-Josef Lenz, Dan Ruderman, and Scott Fraser.

**USC Adolescent and Young Adult Cancer** (AYA@USC) Program According to the NCI, about 89,000 adolescents and young adults, aged 15-39, are diagnosed with cancer in the United States each year. As cancer in young people is more rare, there are many unique challenges facing those patients throughout their cancer


journey. It is important to find the right doctors and hospitals that not only specialize in the treatment of AYA cancer, but also provide holistic and multidisciplinary care to address

To address these challenges, the AYA@USC Program was established in 2013 in a joint effort by USC Norris, the USC Norris Cancer Hospital, Children's Hospital Los Angeles, and Los Angeles County Hospital. The AYA@USC team consists of Co-Medical Directors Drs. David




visit <a href="https://aya.usc.edu">https://aya.usc.edu</a> or contact Shu Li, program administrator, at <a href="mailto:shuli@usc.edu">shuli@usc.edu</a>.

genetic testing at no cost for patients without insurance coverage In the spring of 1996, Judy Goldberg, an LA native still in her forties, was diagnosed with ovarian cancer. In an effort to



**LEARN MORE>>** 



appropriate options for cancer screening and prevention. Deeply impressed by Ms. Culver's efforts, Dr. Kronish made a generous donation on behalf of the foundation to the Cancer Genetics Program at USC Norris. This donation will enable USC Norris to offer genetic testing at no cost for patients without insurance who are

USC Norris receives a new gift to provide

advance the development of new treatments, her husband

**Patient Stories** Always Have Hope. As Long as You Live, There Is Hope.

that both kidneys would need to be removed, which would have left Deborah in need of dialysis and a kidney transplant. Thankfully, she was directed to Dr. Inderbir Gill at USC Norris, who is an internationally recognized leader in the field of robotic and laparoscopic surgery for urologic cancers. Dr. Gill and his exceptional team were ultimately successful in saving 65 percent of Deborah's left kidney function and 60 percent of Deborah's right

"I am confident in USC Norris and I thank God for directing me there because I have found that not every medical facility and not all physicians treat patients with the utmost care and

Roughly a year later in August 2012, Deborah began experiencing pain in her lower back. Consequently, a bone marrow examination was performed by Dr. Casey O'Connell. The test

revealed that Deborah had light chain multiple myeloma, cancer of plasma cells. Though many patients receiving this news would be devasted, Deborah found comfort in her faith affect the blood, bone marrow, and lymph nodes.

respect that I received at USC Norris," said Deborah.

for kidney cancer and nearly eight years for multiple myeloma.

kidney function.

in God. "No matter what I go through in my life, I know God will never leave me nor forsake me," says Deborah. "He is with me every day throughout my entire life's journey, whether it be through my happiness or my struggles. Only He knows what that journey is and how long my life will be." Her treatment was overseen by Drs. Sikander Ailawadhi and Kevin Kelly, both experts in the treatment of hematologic malignancies, which are cancers that

Deborah Coleman was diagnosed with renal cell adenocarcinoma (also known as kidney cancer) in June 2011. Deborah's initial prognosis was grim as the cancer was located towards the center of both her left and right kidneys. Before coming to USC Norris, her physician had told her

friends and family," says Deborah. "Everyone has shown me love. I say love because it is love. They do their work with love and care, and that is what makes USC Norris so special." **New Faculty Spotlight** 


Mohamed Abou-el-Enein, MD, PhD, MSPH

Dr. Mohamed Abou-el-Enein joined USC Norris, the Keck School of Medicine, and Children's Hospital Los Angeles on January 4, 2021, as the inaugural Executive Director of the joint USC/CHLA Cell Therapy Program. He is also the Medical Director of the new cGMP facility for cell and gene therapy that is under construction in the Harlyne J. Norris Research Tower, scheduled for completion in 2022. Through

USC Norris, Deborah is a cancer survivor who has been in remission for nearly nine years

"Hold on to hope, be positive, and laugh. Laughter is medicine for the soul and is healing

Deborah continues to get exceptional care at the USC Norris Cancer Center. "When I go for an appointment at the Larry and Judy Freeman Day Hospital at USC Norris, it's like visiting



March 2, 2021, 12-1 pm Speaker: Jun Yang, PhD Zoom link: https://usc.zoom.us/j/92999635953 For more information, click **HERE**.

development of cell and gene therapy products in top-tier journals such as Cell Stem Cell, British Medical Journal, Lancet Oncology, Molecular Therapy, Nature Biotechnology, and

**Grand Rounds: Investigation of How ECM Stiffness Mediates Chemoresistance in** Pancreatic Cancer March 30, 2021, 12-1 pm Speaker: Reginald Hill, PhD

For more information, click **HERE**.

Zoom Link: https://usc.zoom.us/j/99266525084

Have something to contribute to Community for a Cure? Send it to Hinde. Kast@med.usc.edu

Follow Us on Twitter

**Sollow Us** on Instagram

Follow Us on Twitter

Dr. Amir Goldkorn, USC Norris Associate Director

Freyer and James Hu, who are specialized in pediatric and adult oncology, respectively. Additional team members are Jan Huynh, clinical social worker; Elaine Vieira, nurse navigator; Dr. Aura Kuperberg, special project administrator; and Shu Li, program administrator. The AYA@USC Program addresses the psychosocial needs for cancer patients and survivors to improve their health outcomes and quality of life through clinical care, research, education,

psychological and social concerns for patients.

After the passing of his wife, Dr. Kronish became concerned about potential inherited cancer risks for the children of ovarian cancer patients. As a result, he reached out to Ms. Julie Culver MS, a genetic counselor at USC Norris, whose program provides a concerned family with a comprehensive evaluation to identify inherited cancer risks as well as describe

With hope and faith in God, positivity, laughter, support from her loved ones, and her church family, Deborah faced both her cancers head on and never gave up. Happily, due to the care she received from all of the exceptional medical professionals that treated her at

for the body," says Deborah.

assist investigators in bringing their basic work in cell and gene therapies into clinical testing. Dr. Abou-el-Enein most recently served as Head of the Clinical Development Platform and Head of the Translational Research Unit at the BIH Center for Regenerative Therapies and the Berlin Center for Advanced Therapies, respectively, both at the Charité Medical

these roles, Dr. Abou-el-Enein will work closely with institutional leadership to provide vision and to oversee the development of a "one-stop-shop" translational platform that aims to

**Grand Rounds: Genomics of Racial Disparities in Childhood Leukemia** 

Robert.Weiner@med.usc.edu to learn more about giving to USC Norris.